ストックスクリーナーアプリを入手
3.83
0.00%
0.00
アフターアワーズ：
3.85
0.02
+0.52%
前日終値:
$3.83
開ける：
$3.82
24時間の取引高:
391.89K
Relative Volume:
0.21
時価総額：
$397.87M
収益：
-
当期純損益:
$-166.01M
株価収益率:
-1.8433
EPS:
-2.0778
ネットキャッシュフロー:
$-131.32M
1週間 パフォーマンス:
-4.49%
1か月 パフォーマンス:
-6.81%
6か月 パフォーマンス:
-29.72%
1年 パフォーマンス:
-1.03%
1日の値動き範囲:
$3.79
$3.85
1週間の範囲:
$3.77
$4.075
52週間の値動き範囲:
$2.715
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
3.83 | 432.15M | 0 | -166.01M | -131.32M | -2.0778 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
Why Did Larimar Therapeutics’ Stock Surge Over 30% Pre-Market Today? - stocktwits.com
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns - stocktwits.com
Larimar’s CTI-1601 Study Update Keeps Friedreich’s Ataxia Catalyst in Play - TipRanks
Price to earnings forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Larimar (LRMR) Earnings Snapshot: EPS Prints Above Forecast at the Close; Share Move: The Market Price Advances 2.72%Forward EPS Estimate - vinanet.vn
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Stocktwits
Hennion & Walsh Asset Management Inc. Purchases New Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
Dimensional Fund Advisors LP Purchases 470,968 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
Larimar Therapeutics (LRMR) Holds Ground: Modest Decline Tests Key Support ZoneWatchlist Stock Ideas - dars.gov.et
Larimar Advances FDA Filing as Drug Costs Push Loss Higher - MyChesCo
Renaissance Technologies LLC Has $3.33 Million Position in Larimar Therapeutics, Inc. $LRMR - MarketBeat
Larimar Therapeutics (LRMR) to Announce Earnings on Thursday - marketbeat.com
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp - The Globe and Mail
William Blair Maintains Larimar Therapeutics(LRMR.US) With Buy Rating - Moomoo
LRMR Maintained by Wedbush -- Price Target Lowered to $11.00 - GuruFocus
Wedbush Cuts Larimar Therapeutics (NASDAQ:LRMR) Price Target to $11.00 - MarketBeat
LifeSci Capital Maintains Larimar Therapeutics(LRMR.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Larimar Therapeutics (LRMR) Advances Nomlabofusp Submission Amid Mixed Financial Signals - GuruFocus
Larimar Therapeutics 2Q 2026: Net loss $32.8M, Diluted EPS $(0.30) — 10-Q Summary - TradingView
Larimar Therapeutics Reports Positive Longer-Term Nomlabofusp Data and Progress Toward Rolling BLA Submission for Friedreich’s Ataxia - Quiver Quantitative
Larimar: Q2 Earnings Snapshot - marketscreener.com
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update - Yahoo Finance
Larimar Therapeutics (LRMR) Gains 3.27% as Biotech Stock Approaches Key $4.32 ResistanceBuy Signal Reports - vinanet.vn
LRMR Q1 2026 Earnings: Loss Narrows to -$0.31 Per Share, Beating Estimates by 43.19%Pre-Earnings Setup - vinanet.vn
LRMR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Larimar Therapeutics Inc (LRMR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Larimar Therapeutics Inc (LRMR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Larimar Therapeutics Inc (LRMR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Larimar Therapeutics Inc (LRMR) Institutional Confidence - TradingKey
LRMR|Larimar Therapeutics Inc|Price:3.820|Chg%:-0.180 - TradingKey
Enterprise value to EBITDA forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
TradingKey - TradingKey
Larimar Therapeutics Market Sentiment - Benzinga España
Larimar Therapeutics, Inc. Revenue Breakdown – NASDAQ:LRMR - tradingview.com
What Just Happened with Larimar Therapeutics (LRMR) and Why Does it Matter - Kavout | AI
LRMR|Larimar Therapeutics Inc|Price:4.000|Chg%:-0.010 - TradingKey
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc.LRMR - PR Newswire
Price to earnings forward of Larimar Therapeutics, Inc. – SWB:ZA71 - TradingView
Larimar Therapeutics Files First Module of BLA for Nomlabofusp in Friedreich's Ataxia TreatmentNew Analyst Coverage - dars.gov.et
Larimar Therapeutics Initiates BLA Submission for Nomlabofusp in Friedreich’s AtaxiaProfit Guidance Range - dars.gov.et
Larimar Therapeutics Files Initial BLA Module for Nomlabofusp in Friedreich's AtaxiaPre-Announcement Alert - dars.gov.et
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy - Yahoo Finance
User - The Chronicle-Journal
Price to earnings forward of Larimar Therapeutics, Inc. – LS:A2P5PP - TradingView
Price to sales forward of Larimar Therapeutics, Inc. – NASDAQ:LRMR - TradingView
Thomas Hamilton Bought 6.1% More Shares In Larimar Therapeutics - Moomoo
Larimar Therapeutics stock jumps on insider purchase By Investing.com - Investing.com South Africa
Larimar Therapeutics stock jumps on insider purchase - Investing.com
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):